跳至主要内容
临床试验/NCT00646360
NCT00646360已完成不适用

Effects of Prenatal DHA Supplements on Infant Development

Emory University1 个研究点 分布在 1 个国家目标入组 1,094 人开始时间: 2005年2月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
1,094
试验地点
1
主要终点
Changes in infant height

研究概览

简要总结

This research study research is about the significance of polyunsaturated fatty acids (PUFAs) for human development. Specifically, the study team will assess the effect of docosahexanoic acid (DHA) supplementation during pregnancy on infant growth and development through a randomized controlled intervention trial in Cuernavaca, Mexico. This is a collaborative effort between the Rollins School of Public Health, Emory University, the Instituto Nacional de Salud Publica (INSP) and the Instituto Mexicano del Seguro Social (IMSS), Cuernavaca, Mexico. Pregnant women attending the IMSS General Hospital I are recruited between 18-22 weeks gestation and assigned randomly to receive either DHA (400 mg) or a placebo daily until delivery. The main study outcomes include a) birth outcomes: birth size, gestational age, cord blood levels of DHA and neurodevelopment b) maternal blood and breast milk DHA levels at 1 and 3 months post-partum, c) postnatal growth and development during the first 5 years of age and d) infant DHA status at 3, 12 and 18 months.

详细描述

This research study is about the significance of polyunsaturated fatty acids (PUFAs) for human development. Specifically, the study team will assess the effect of docosahexanoic acid (DHA) supplementation during pregnancy on infant growth and development through a randomized controlled intervention trial in Cuernavaca, Mexico. This is a collaborative effort between the Rollins School of Public Health, Emory University, the Instituto Nacional de Salud Publica (INSP) and the Instituto Mexicano del Seguro Social (IMSS), Cuernavaca, Mexico. Pregnant women attending the IMSS General Hospital I are recruited between 18-22 wks gestation and assigned randomly to receive either DHA (400 mg) or a placebo daily until delivery. The main study outcomes include a) birth outcomes: birth size, gestational age, cord blood levels of DHA and neurodevelopment b) maternal blood and breast milk DHA levels at 1 and 3 mo post-partum c) postnatal growth and development during the first 5 years of age and d) infant DHA status at 3, 12 and 18 mo. All data collection is carried out at the study headquarters (IMSS) except for home environment that is assessed during home visits. Physical growth (length, weight, and head circumference) and infant and child development (visual and auditory evoked potentials, visual attention, Bayley scales of infant development, McCarthy child development score, Hearts and Flowers stroop test, and other computerized child development tests) are measured at birth, 1, 3, 6, 9, 12, 18, 24, 36 months and at 4 and 5 years of age by trained workers. Data are also obtained on socioeconomic status, obstetric history, maternal diet, anthropometry and intelligence, quality of home environment and infant feeding practices. Data analysis will include group comparisons (intent-to-treat) after ensuring effectiveness of randomization, and structural equation modeling to examine the various pathways by which DHA supplementation during pregnancy affects child growth and development. The findings of this project will contribute significantly to our understanding of the functional consequences of DHA supplementation during pregnancy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
Female
接受健康志愿者
是

入选标准

  • •18-22 weeks pregnant (based on last menstrual period)
  • •18 - 35 years old
  • •Resident of Cuernavaca who intends to deliver at the IMSS General Hospital I and remain in the area for the 2 years following recruitment
  • •Intends to predominantly breastfeed infant until 3 months of age
  • •Agrees to participate with informed consent

排除标准

  • •High risk pregnancy: If documented in the clinical record at recruitment and will include history and prevalence of abruptio placentae, any serious bleeding episode in the current pregnancy, gestational diabetes, pregnancy induced hypertension, maternal toxoplasmosis infection during pregnancy, coagulation disorders, thrombocytopenia or chronic vascular, renal or systemic disease and drug use.
  • •Lipid metabolism (hyperlipidemia) and/or absorption disorders
  • •Regular intake of fish oil or DHA supplements during pregnancy
  • •Chronic use of medication for illnesses like epilepsy

研究组 & 干预措施

Placebo arm

Placebo Comparator

Pregnant women attending the IMSS General Hospital I are recruited between 18-22 wks gestation and assigned randomly to receive either DHA (400 mg) or a placebo daily until delivery.

干预措施: Placebo (Dietary Supplement)

DHA arm

Experimental

Docosahexonic acid (DHA) (400 mg/day). Pregnant women attending the IMSS General Hospital I are recruited between 18-22 wks gestation and assigned randomly to receive either DHA (400 mg) or a placebo daily until delivery.

干预措施: DHA (Dietary Supplement)

结局指标

主要结局

Changes in infant height

时间窗: Birth, months 1, 3, 6, 9, 12, 18, 24, 36 and at 4 and 5 years of age

Infants will be measured in the hospital and at all check-ups. Height is measured in centimeters (cm).

Changes in child development score

时间窗: 1, 1.5 and 5 years of age

The Bayley Scales of Infant Development -II are used to assess child development during the first two years of life while The McCarthy Scales of Children's Abilities (MSCA) is a psychological instrument for young children that measures cognitive ability in six domain areas: Verbal, Perceptual-Performance, Quantitative, General Cognitive, Memory, and Motor at age 5 y.

Birth size

时间窗: Birth

Birth size will be determined by measuring the newborn, a baby's length is measured from the top of their head to the bottom of one of their heels.

Gestational age

时间窗: Birth

Gestational age is measured in weeks, from the first day of the woman's last menstrual cycle to the current date.

Changes in visual evoked potentials

时间窗: 3 and 6 months of age

Visual evoked potential (VEP) is an electrical signal emanated from the brain while a visual stimulus is presented to the subject in a time locked manner. The VEP can be used as a diagnostic tool to detect ocular diseases in patients with visually impaired. VEP response can also be used to detect eye diseases like glaucoma, diabetic retinopathy, multiple sclerosis, ocular hypertension, loss of peripheral (side) vision, macular degeneration and color blindness.

Changes in infant weight

时间窗: Birth, months 1, 3, 6, 9, 12, 18, 24, 36 and at 4 and 5 years of age

Infant weight is measured in kilograms (kg) and weight is measured in the hospital and at all check-ups.

Changes in auditory evoked potentials

时间窗: 1 and 3 months of age

A brainstem auditory evoked response (BAER) test measures how the brain processes the sounds a person hears. The BAER test records the subject's brainwaves in response to clicks or other audio tones that are played for them.

Changes In infant head circumference

时间窗: Birth, months 1, 3, 6, 9, 12, 18, 24, 36 and at 4 and 5 years of age

Head circumference or OFC \[occipital frontal circumference\] is measured over the most prominent part on the back of the head (occiput) and just above the eyebrows (supraorbital ridges). This can be translated to mean the largest circumference of the head. Head circumference is measured in centimeters (cm).

Changes in Hearts and Flowers Stroop Test

时间窗: 5 years of age

This tests working memory, response inhibition, and task switching/cognitive flexibility . The task requires participants to press a response button that is either on the same side (congruent) or opposite side (incongruent) of an image. When children see an image of a heart, they are instructed to press the corresponding directional arrow button on a keyboard. When children see an image of a flower, they are instructed to press the opposite directional arrow button on the keyboard . The task consists of three separate levels that contain only congruent trials (12 trials total), only incongruent trials (12 trials total), and mixed congruent and incongruent trials respectively (33 trials total). Images are presented on a computer monitor. Before both the congruent and incongruent trial blocks, a training period is administered which consists of 5 trials. The child is unable to advance to the next question until they respond correctly.

次要结局

  • Changes Immune function(first 6 months of life)
  • Changes in Morbidity(Birth, months 1, 3, 6, 9, 12, 18, 24, 36 and at 4 and 5 years of age)
  • Cognitive outcomes at age 7 years of age(At 7 year follow up)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Usha Ramakrishnan

Professor

Emory University

研究点 (1)

Loading locations...

相似试验